Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03512262 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

A Phase 3 study, sponsored by Radius Health.

Completed
Registry status
Phase 3
Development phase
228
Enrollment target

NCT03512262 is a Phase 3 study that has completed, run by Radius Health. The registered enrollment target is 228 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03512262, a Phase 3 study, has completed, sponsored by Radius Health.

COMPLETED
Registry status
Phase 3
Development phase
228 participants
Enrollment target

Study Summary

A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.

Interventions

  • DRUG Placebo
  • DRUG Abaloparatide

Trial Details

FieldValue
Enrollment Target 228 participants
Start Date 2018-05-03
Est. Completion 2021-09-08
Phase Phase 3

Sponsor

Radius Health

11 total trials

What the Registry Record Tells You About NCT03512262

The ClinicalTrials.gov registry entry for NCT03512262 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radius Health, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03512262 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03512262 about?

NCT03512262 is a clinical study titled "Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)". A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.

What is the current status of trial NCT03512262?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 228 participants. The study started on 2018-05-03. Estimated completion is 2021-09-08.

What interventions are being tested in trial NCT03512262?

The interventions under investigation include: Placebo (DRUG), Abaloparatide (DRUG).

Who is sponsoring clinical trial NCT03512262?

This trial is sponsored by Radius Health, which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.